California-based Coda Genomics Inc. has changed its name to Verdezyne Inc. and refined its focus on the industrial biotechnology sector.
The name change announced Nov. 11, followed the announcement of Stephen Picataggio as chief scientific officer. Under Picataggio’s leadership, the company is planning to expand the scientific team to support new initiatives. “I’m convinced Verdezyne’s technology has tremendous potential for metabolic pathway engineering in the industrial biotechnology sector, and I’m delighted to join their management team to help establish a scientific roadmap and commercialization strategy to improve the commercial production of platform chemicals and biofuels,” Picataggio said.
Verdezyne employs proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways and microorganisms. The company creates and harnesses biological diversity to optimize commercial fermentation processes used to manufacture platform chemicals and biofuels. In the past, Verdezyne has worked on engineering yeast for biofuel production, as well as synthetic gene production and several pharmaceutical projects.
Article Continues After Advertisement
“This is a very exciting time for our company. We have a highly experienced management team in place, a solid business plan that includes significant internal R&D efforts and strategic relationships with key industrial partners,” said E. William Radany, Verdezyne’s president and chief executive officer. “Our new name and focus solidifies our commitment to the burgeoning industrial biotechnology marketplace.”